Results 271 to 280 of about 546,892 (350)
The impact of intravenous immunoglobulin therapy on resource utilization associated with viral respiratory tract infections. [PDF]
Azar A +5 more
europepmc +1 more source
What's New? Following the Chernobyl disaster, workers were recruited from formerly Soviet‐occupied areas, including Lithuania, to participate in clean‐up efforts. Radiation exposure incurred by workers during these efforts offers a unique opportunity for the study of long‐term health effects.
Rita Steponaviciene +3 more
wiley +1 more source
Comparative Meta-Analysis of Long-Read and Short-Read Sequencing for Metagenomic Profiling of the Lower Respiratory Tract Infections. [PDF]
Lorenzin G, Carlin M.
europepmc +1 more source
What's New? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke +30 more
wiley +1 more source
Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis. [PDF]
Soudani S +8 more
europepmc +1 more source
Abstract Background Respiratory syncytial virus (RSV) is a leading cause of hospitalization and mortality in early infancy. Maternal immunization offers a preventive strategy, but uncertainties regarding safety and economic value have limited its implementation.
Johnatan Torres‐Torres +10 more
wiley +1 more source
Parental knowledge, attitudes, and practices toward antibiotic use for childhood Upper Respiratory Tract Infections in Khartoum, Sudan. [PDF]
Yousif RA +5 more
europepmc +1 more source
Antibody protection from SARS-CoV-2 respiratory tract exposure and infection
Alex Chen +2 more
openalex +1 more source
mRNA Vaccination for Treating Allergy by Modulating Allergen‐Specific Immunity
This News and Views article discusses the rationale for anti‐allergy vaccine development using a lipid nanoparticle‐mRNA platform. The authors provide additional evidence that supports the potential of using the mRNA approach to combat allergic diseases.
Kun Guo +4 more
wiley +1 more source

